Doxorubicin News and Research

RSS

Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.

Researchers discover novel protein that governs metastasis and chemoresistance in pediatric bone cancer

Human osteosarcoma samples are hard to come by, making the disease difficult to study. However, K9 bone cancer is genetically indistinguishable from the human form of the disease, and over 10,000 canine patients develop the disease every year.

10 Apr 2013

Clinigen announces acquisition of Cardioxane from Novartis

Clinigen Group plc today announced the acquisition of Cardioxane (dexrazoxane) from Novartis for US$33 million in cash, payable in two tranches.

From Clinigen Group 26 Mar 2013

Study shows how nanoparticles can be formed to efficiently carry cancer drugs to tumor cells

Small particles loaded with medicine could be a future weapon for cancer treatment. A recently-published study shows how nanoparticles can be formed to efficiently carry cancer drugs to tumor cells. And because the particles can be seen in MRI images, they are traceable.

7 Mar 2013

Study shows how theranostic nanoparticles can effectively deliver cancer drugs to tumour cells

Tiny particles filled with a drug could be a new tool for treating cancer in the future. A new study published by Swedish scientists in Particle & Particle Systems Characterization shows how such nanoparticles can be combined to secure the effective delivery of cancer drugs to tumour cells - and how they can be given properties to make them visible in MR scanners and thus rendered trackable.

1 Mar 2013

BioAlliance Pharma to extend Validive phase II trial in head and neck cancer

BioAlliance Pharma SA, an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the extension of its phase II clinical trial with Validive in the United States in radio/chemotherapy-induced oral mucositis prevention in patients with head and neck cancer.

15 Feb 2013

Surgery could boost chemotherapy outcomes in canine TCC

Dogs that undergo curative surgery for transitional cell carcinoma before initiating a combination of doxorubicin and piroxicam therapy have significantly longer median overall survival than their counterparts not pretreated surgically, report researchers.

6 Feb 2013

Sun Pharma receives FDA approval for generic Doxil

The U.S. Food and Drug Administration today approved the first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection).

4 Feb 2013

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.

1 Feb 2013

Celsion's ThermoDox does not meet primary endpoint in Phase III HCC study

Celsion Corporation, a leading oncology drug development company, today announced that ThermoDox in combination with radiofrequency ablation (RFA) did not meet the primary endpoint of the Phase III HEAT Study in patients with hepatocellular carcinoma (HCC), also known as primary liver cancer.

31 Jan 2013

KLF8 protein could be helpful in preventing cancer recurrence

Just as the body can become resistant to antibiotics, certain methods of killing cancer tumors can end up creating resistant tumor cells. But a University of Central Florida professor has found a protein present in several types of cancer, including breast and ovarian cancer, which could be helpful in preventing tumors from coming back.

29 Jan 2013

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas.

28 Jan 2013

Aeterna Zentaris reaches SPA agreement with FDA for AEZS-108 Phase 3 trial in endometrial cancer

Aeterna Zentaris Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration ("FDA") on a Special Protocol Assessment ("SPA") for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. The SPA agreement states that the proposed trial protocol design, clinical endpoints and planned analyses are acceptable to the FDA to support a regulatory submission.

29 Dec 2012

Merrimack announces results from MM-302 Phase I trial on advanced HER2 positive breast cancer

Merrimack Pharmaceuticals, Inc. today announced Phase I clinical trial results for MM-302, the company's novel agent for the treatment of advanced HER2 positive (HER2+ or ErbB2+) breast cancer.

11 Dec 2012

Tufts University researchers demonstrate silk-based implantable optics

Tufts University School of Engineering researchers have demonstrated silk-based implantable optics that offer significant improvement in tissue imaging while simultaneously enabling photo thermal therapy, administering drugs and monitoring drug delivery. The devices also lend themselves to a variety of other biomedical functions.

29 Nov 2012

Merrimack’s MM-302 Phase I results and MM-DX-929 preclinical data to be presented at SABCS

Merrimack Pharmaceuticals, Inc. today announced that Phase I data evaluating the novel agent MM-302 for the treatment of advanced HER2+ breast cancer and preclinical data on potential imaging and biomarker-based diagnostics will be presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), Dec. 4-8, 2012 in San Antonio, Texas.

28 Nov 2012

Doxorubicin News and Research

Researchers discover novel protein that governs metastasis and chemoresistance in pediatric bone cancer

Clinigen announces acquisition of Cardioxane from Novartis

Study shows how nanoparticles can be formed to efficiently carry cancer drugs to tumor cells

Study shows how theranostic nanoparticles can effectively deliver cancer drugs to tumour cells

BioAlliance Pharma to extend Validive phase II trial in head and neck cancer

Surgery could boost chemotherapy outcomes in canine TCC

Sun Pharma receives FDA approval for generic Doxil

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Celsion's ThermoDox does not meet primary endpoint in Phase III HCC study

KLF8 protein could be helpful in preventing cancer recurrence

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Aeterna Zentaris reaches SPA agreement with FDA for AEZS-108 Phase 3 trial in endometrial cancer

Merrimack announces results from MM-302 Phase I trial on advanced HER2 positive breast cancer

Tufts University researchers demonstrate silk-based implantable optics

Merrimack’s MM-302 Phase I results and MM-DX-929 preclinical data to be presented at SABCS

No advantage of continuous over bolus doxorubicin in ALL children

New gene delivery vehicle opens route to the heart of cells in solid tumors

Drug trio may reduce eliminate cardiac side effects of doxorubicin

Scientists identify mechanism via Top2b enzyme that drives doxorubicin-induced heart damage

Azaya Therapeutics commences ATI-0918 bioequivalence study in ovarian cancer

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News